BACKGROUND Sipuleucel-T is a US Food and Drug Administration-approved immunotherapy for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Its mechanism of action is not fully understood. This prospective trial evaluated the direct immune effects of systemically administered sipuleucel-T on prostatic cancer tissue… (More)
— In this paper, we present mBenchLab, a software infrastructure to measure the Quality of Experience (QoE) on tablet and smartphones accessing cloud hosted Web services. mBenchLab does not rely on emulation but uses real phones and tablets with their original software stack and communication interfaces for performance evaluation. We have used mBenchLab to… (More)
Sipuleucel T is an autologous cellular immunotherapy designed to stimulate an immune response in men diagnosed with asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer. Sipuleucel T improves overall survival and provides an additional treatment option for this patient population.